Dr. Sanjeev Redkar is a co-founder of CBT Pharmaceuticals, Inc. that was started as a spin-off in early 2016. In his previous role, Dr. Redkar was the Senior Vice President of Product Development at Astex Pharmaceuticals, an Otsuka company, responsible for pharmaceutical development, technical operations and manufacturing. Dr. Redkar has been closely involved in preclinical and clinical development as well as global launches of several drugs including Dacogen and Nipent.
Dr. Redkar is a co-inventor of guadecitabine, a novel hypomethylating agent now in Phase 3 clinical trials. He has over 20 years of oncology drug development experience and has several peer-reviewed publications and patents. Dr. Redkar earned his doctorate from the University of Colorado, Boulder, a MBA from St. Mary’s College of California, and an undergraduate at the Indian Institute of Technology, Bombay. Dr. Redkar is an Adjunct faculty and a Board Member at the University of the Pacific School of Pharmacy, Stockton and Chairman of the Board of EPPIC, a pharmaceutical professional’s network.
Gavin Choy joined CBT Pharmaceuticals, Inc. in August 2016 as EVP and Chief Operating Officer. Prior to joining CBT, Gavin was the Senior Vice President of Clinical Sciences and Operations at Galena Biopharma, Inc., where he led the clinical development of the cancer vaccine programs. Prior to joining Galena, Dr. Choy was the Vice President of Clinical Sciences and Operations at Astex Pharmaceuticals, a subsidiary of Otsuka Pharmaceuticals, and has had leadership roles at SuperGen, Hana Biosciences, and Gilead Sciences.
Prior to industry practice, Dr. Choy was a clinical pharmacologist in medical oncology, hematology, and bone marrow transplantation at Stanford University Hospital and Clinics; Director, Geriatric Pharmacy Residency Programs, American Society of Health System Pharmacists accredited; Assistant Clinical Professor of Pharmacy Practice at University of California, San Francisco, University of Southern California; Pharmacy Faculty Advisor, University of California, Los Angeles, Department of Medicine and Stanford University School of Medicine. Dr. Choy received a doctorate in pharmacy from the University of Southern California, completed post-doctorate training at the Department of Veteran Affairs, and holds a master in business administration in health care at the Paul Merage School of Business, University of California, Irvine.
Dr. Kanekal is a board-certified regulatory professional and a board-certified Toxicologist with 23-years of biotechnology and pharmaceutical industry experience. He is a veterinarian and has a PhD. in Pharmacology and Toxicology from the University of California at Davis and has conducted post-doctoral research at the School of Pharmacy, University of Texas in Austin. He is a veteran in regulatory strategy and safety assessment of small molecules and biologics, of both new molecular entities and reformulated drugs.
Dr. Kanekal has a track record of rapidly moving early-stage drugs into clinical development to obtain clinical proof-of-concept, and to eventual NDA/BLA. He has managed regulatory and non-clinical safety programs for several drugs and was responsible for over 40 IND/NDA/BLA approvals, including over 15 cancer pharmaceuticals such as Bexxar (anti-CD20 Ab), Treanda, Synribo etc. for various indications including AML, CML, CLL, NHL, GBM, NSCLC, H&N, etc. He has conducted several successful meetings with FDA and participated in FDA advisory committee meetings (ODAC). He previously held leadership positions with Novartis (Chiron), GSK (Corixa), Teva (Cephalon, Salmedix, ChemGenex), Astex (SuperGen), Absorption Systems and Reviva.
Dr. Tillman Pearce served as Chief Medical Officer for the publicly traded oncology company, Threshold Pharmaceuticals, from 2012 to 2017 and for the monoclonal antibody company, KaloBios Pharmaceuticals, from 2007 through 2011. Previously he led the European office for the San Francisco Bay Area monoclonal antibody company, PDL Biopharma and had been the Medical Director for the Oncology Business Unit at Sanofi/Sanofi~Synthelabo where he was responsible for the lifecycle management strategy for the colorectal cancer drug oxaliplatin Eloxatin. Dr Pearce started his pharmaceutical career at Sandoz/Novartis Pharmaceuticals in New Jersey and in Basle, Switzerland. Dr. Pearce received his M.D. from the Medical College of Georgia and is board-certified in both internal medicine and hematology.